肿瘤体积对Ⅰ期非小细胞肺癌术后患者预后预测价值的研究

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (769 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨肿瘤体积预测Ⅰ期非小细胞肺癌根治术后患者预后的价值。方法回顾性分析2007年1月～2010年12月收入中山大学肿瘤防治中心并接受根治性手术、术后病理为Ⅰ期非小细胞肺癌患者203例，比较肿瘤体积＜8.35 cm3和肿瘤体积≥8.35 cm3两组患者的总生存率和无病生存期，并纳入COX多因素分析。结果两组在性别、吸烟、病理类型、病理分期、分化程度、支气管壁侵犯方面比较，差异有统计学意义（P ＜ 0.05）。在多因素分析中，肿瘤体积是Ⅰ期非小细胞肺癌预后一个独立的预测因子（HR=2.972，95%CI：1.566～5.637，P ＜ 0.01）。生存分析结果显示肿瘤体积＜8.35 cm3患者5年总生存率为88.5%，肿瘤体积≥8.35cm3患者5年OS为74.0%（P ＜ 0.01）。肿瘤体积＜8.35 cm3预示更长的无病生存期（P ＜ 0.01）。结论肿瘤体积是Ⅰ期非小细胞肺癌OS和PFS的独立预测因素，术前CT测定肿瘤体积有助于评估患者的预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	魏振强谢昊均苏晓东

关键词 ：肿瘤体积, Ⅰ期非小细胞肺癌, 预后

Abstract：Objective To investigate the value of tumor volume in predicting the prognosis of patients with stage I non-small cell lung cancer (NSCLC) after radical surgery. Methods Two hundred and Three patients with radical surgery and postoperative pathology was stage Ⅰ NSCLC from January 2007 to December 2010 in Sun Yat-sen University Cancer Center was retrospectively reviewed. The overall survival and disease-free survival in patients were compared between tumor volume ＜8.35 cm3 and tumor volume ≥8.35 cm3 through COX multivariate analysis. Results There were significant differences between the two groups in terms of characteristics of sex, smoking history, histological type, pathological stage, degree of differentiation and bronchial wall invasion (P ＜ 0.05). In multivariate analysis, tumor volume was an independent predictor for the prognosis of stage I NSCLC (HR=2.972, 95% CI：1.566-5.637, P ＜ 0.01). Survival analysis showed that the 5 year overall survival rates (OS) was 88.5% and 74% in tumor volume ＜8.35 cm3 group and tumor volume ≥8.35 cm3 (P ＜ 0.01) respectively. Tumor volume <8.35 cm3 indicated a longer progress-free survival (P ＜ 0.01). Conclusion Tumor volume is an independent predictor of OS and PFS in stage I NSCLC. Preoperative CT measurement of tumor volume helps to assess the prognosis of patients.

Key words： Tumor volume StageⅠnon-small cell lung cancer Prognosis

基金资助:广东省科技计划项目（2012B031800070）。

通讯作者: 苏晓东（1968.10-），男，博士，副主任医师，硕士生导师；研究方向：胸部肿瘤（肺癌、食管癌、乳腺癌和纵隔肿瘤）的外科治疗和综合治疗。

作者简介: 魏振强（1991.6-），男，硕士；研究方向：肿瘤耐药的机制。

引用本文:

魏振强谢昊均苏晓东. 肿瘤体积对Ⅰ期非小细胞肺癌术后患者预后预测价值的研究[J]. 中国医药导报, 2018, 15(8): 104-107,123.
WEI Zhenqiang XIE Haojun SU Xiaodong. Study on prognostic predictive value of tumor volume in patients with stage Ⅰ non-small cell lung cancer. 中国医药导报, 2018, 15(8): 104-107,123.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I8/104

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics for Hispanics/Latinos [J]. CA Cancer J Clin，2015，65（6）：457-480.
[2] 姚晓军，刘伦旭.肺癌的流行病学及治疗现状[J].现代肿瘤医学，2014，22（8）：1982-1986.
[3] Goldstraw P，Crowley J，Chansky K，et al. The IASLC Lung Cancer Staging Project：proposals for the revision of the TNM stage groupings in the forthcoming（seventh）edition of the TNM Classification of malignant tumours [J]. J Thorac Oncol，2007，2（8）：706-714.
[4] 罗斌，田建辉，刘嘉湘.循环肿瘤细胞免疫逃逸的研究进展[J].中华肿瘤防治杂志，2015，22（23）：1856-1860.
[5] Koo TR，Moon SH，Lim YJ，et al. The effect of tumor volume and its change on survival in stage Ⅲ non-small cell lung cancer treated with definitive concurrent chemoradiotherapy [J]. Radiation oncology，2014，9（1）：283.
[6] 马高，许晓泉，胡昊，等.基于MR图像的原发肿瘤体积测量与鼻咽癌2008分期的相关性研究[J].南京医科大学学报：自然科学版，2017，27（4）：504-507.
[7] Lin CS，de Oliveira Santos AB，Silva EL，等.肿瘤体积作为口腔鳞癌患者较低生存率的独立预测因素[J].中国口腔颌面外科杂志，2017，14（3）：285.
[8] Teng XD. World Health Organization classification of tumours，pathology and genetics of tumours of the lung [J]. Chinese J Pathol，2005，34（8）：544-546.
[9] Detterbeck FC，Marom EM，Arenberg DA，et al. The IASLC Lung Cancer Staging Project：Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the TNM Classification [J]. J Thorac Oncol，2016，11（5）：666-680.
[10] Winer-muram HT，Jennings SG，Tarver RD，et al. Volumetric growth rate of stage I lung cancer prior to treatment：serial CT scanning [J]. Radiology，2002，223（3）：798-805.
[11] Jennings SG，Winer-muram HT，Tarver RD，et al. Lung tumor growth：assessment with CT--comparison of diameter and cross-sectional area with volume measurements [J]. Radiology，2004，231（3）：866-871.
[12] 王争君，朱琳燕.食管癌患者肿瘤体积对T分期及预后的影响分析[J].实用癌症杂志，2016，（1）：117-119.
[13] Ball DL，Fisher RJ，Burmeister BH，et al. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy：a prospective，observational prognostic factor study of the Trans-Tasman Radiation Oncology Group （TROG 99.05） [J]. Radiother Oncol，2013， 106（3）：305-311.
[14] Zhao BS，Oxnard GR，Moskowitz CS，et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development [J]. Clin Cancer Res，2010，16（18）：4647-4653.
[15] Liu HP，Chen P，Wroblewski K，et al. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times [J]. Nucl Med Commun，2016，37（1）：50-56.
[16] Kim K，Kim SJ，Kim IJ，et al. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer [J]. Nucl Med Commun，2012，33（6）：613-620.
[17] Yoo IR，Chung SK，Park HL，et al. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis [J]. Biomed Mater Eng，2014，24（6）：3091-3103.
[18] Huang W，Liu B，Fan M，et al. The early predictive value of a decrease of metabolic tumor volume in repeated（18）F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy [J]. Eur J Radiol，2015，84（3）：482-488.
[19] Maeda R，Yoshida J，Ishii G，et al. Risk factors for tumor recurrence in patients with early-stage（stage Ⅰ and Ⅱ）non-small cell lung cancer：patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification [J]. Chest，2011，140（6）：1494-1502.
[20] Carter G C，Barrett AM，Kaye JA，et al. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer [J]. Cancer Manag Res，2014， 6：437-449.